

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed, directly or indirectly, in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase, or subscribe for any securities of the Company.

This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions where such offer is unlawful. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.



CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

On February 15, 2026, the Company entered into the Subscription Agreement with the Subscriber, pursuant to which the Company has conditionally agreed to issue, and the Subscriber has conditionally agreed to subscribe for, an aggregate of 84,033,613 Subscription Shares at the Subscription Price of HK\$2.38 per Subscription Share.

The Subscription Price of HK\$2.38 per Subscription Share represents: (a) a discount of approximately 14.70% to the closing price of HK\$2.79 per Share as quoted on the Stock Exchange on February 13, 2026, being the Last Trading Day; and (b) a discount of approximately 19.81% to the average closing price of HK\$2.968 per Share as quoted on the Stock Exchange for the last five consecutive trading days up to and including the Last Trading Day, being the last trading day immediately prior to the date on which the Subscription Price is fixed.

The gross proceeds of the Subscription will amount to approximately HK\$200,000,000 and the net proceeds receivable by the Company under the Subscription are estimated to be approximately HK\$199,000,000 after deducting the relevant expenses incurred in relation to the Subscription. The net issue price per Subscription Share is HK\$2.37. The Company intends to use the net proceeds from the Subscription for (i) working capital and registration maintenance of commercialized products; (ii) research and development expenses for existing pipeline of products and (iii) settling trade payables of the Group.

An application will be made by the Company to the Stock Exchange for the listing of, and the permission to deal in, the Subscription Shares on the Stock Exchange.

Closing is subject to fulfilment (or, where appropriate, waiver) of the conditions precedent under the Subscription Agreement. As the Subscription may or may not proceed, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

On February 15, 2026, the Company entered into the Subscription Agreement with the Subscriber, pursuant to which the Company has conditionally agreed to issue, and the Subscriber has conditionally agreed to subscribe for, an aggregate of 84,033,613 Subscription Shares at the Subscription Price of HK\$2.38 per Subscription Share.

The principal terms of the Subscription Agreement are set out below:

THE SUBSCRIPTION AGREEMENT

Date

February 15, 2026

Parties to the Subscription Agreement

- (1) The Company
- (2) The Subscriber

Information on the Subscriber

The Subscriber is a limited partnership formed under the laws of Hong Kong. It focuses on supporting Biopharmaceutical, Biotechnological, Medical and Healthcare companies. The Subscriber is an indirect-wholly owned entity of WuXi Biologics (Cayman) Inc. (藥明生物技術有限公司*) (“**WuXi Biologics**”), a global biologics contract research, development and manufacturing organization offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide, with its shares being listed on the Main Board of the Stock Exchange (stock code: 2269). The entire limited partnership interests of the Subscriber are wholly owned by WuXi Biologics as at the date of this announcement.

To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, as at the date of this announcement, the Subscriber and its ultimate beneficial owner are third parties independent of and not connected with the Company and its connected persons. As at the date of this announcement, the Subscriber holds 12,826,080 Shares of the Company, representing approximately 2.51% of the Company's issued share capital as at the date of this announcement.

The Subscriber has indicated that, other than the Subscription, it has no intention to acquire any controlling stake or become a controlling shareholder in the Company either by itself or with other third parties within three years from the date of the Subscription Agreement.

Number of Subscription Shares

Assuming that there will be no change in the number of issued Shares between the date of this announcement and the Closing Date, the number of 84,033,613 Subscription Shares under the Subscription represents approximately 16.44% of the number of existing issued Shares as at the date of this announcement and approximately 14.12% of the number of issued Shares as enlarged by the allotment and issue of the Subscription Shares. The aggregate nominal value of the Subscription Shares to be allotted and issued will be US\$840.33613.

Subscription Price

The Subscription Price of HK\$2.38 per Subscription Share represents: (a) a discount of approximately 14.70% to the closing price of HK\$2.79 per Share as quoted on the Stock Exchange on February 13, 2026, being the Last Trading Day; and (b) a discount of approximately 19.81% to the average closing price of HK\$2.968 per Share as quoted on the Stock Exchange for the last five consecutive trading days up to and including the Last Trading Day, being the last trading day immediately prior to the date on which the Subscription Price is fixed.

The Subscription Price was determined with reference to the market conditions and the prevailing market price of the Shares and was negotiated on an arm's length basis between the Company and the Subscriber. The Directors consider that the Subscription Price and the terms and conditions of the Subscription Agreement are fair and reasonable and are in the interests of the Company and the Shareholders as a whole.

Conditions precedent of the Subscription

Closing of the Subscription under the Subscription Agreement shall be conditional upon the following conditions precedent being fulfilled (or, where appropriate, being waived by the relevant party(ies) to such Subscription Agreement (as the case may be)) on or before the Long Stop Date ("**Conditions**"):

- (a) the Board having approved the entering into of the Subscription Agreement and the transactions contemplated under the Subscription Agreement (including but not limited to the allotment and issuance of the Subscription Shares to the Subscriber);

- (b) the Stock Exchange granting approval for the listing of and permission to deal in the Subscription Shares and such listing and permission not subsequently being revoked prior to the Closing;
- (c) all necessary approvals and permission in connection with the Subscription Agreement and the transactions contemplated under the Subscription Agreement having been obtained by the Company;
- (d) the Subscriber having obtained all approvals and permission in connection with the Subscription Agreement and the transactions contemplated thereunder;
- (e) the representations and warranties made by the Company pursuant to the Subscription Agreement being true and accurate in all material respects as of the date of the Subscription Agreement and up to the Closing Date;
- (f) the representations and warranties made by the Subscriber pursuant to the Subscription Agreement being true and accurate in all material respects as of the date of the Subscription Agreement and up to the Closing Date; and
- (g) each of the Company and the Subscriber having carried out and complied with the Subscription Agreement and obligations which are required to be carried out and complied by each of them prior to the Closing Date in all material respects.

For the avoidance of doubt, Conditions under paragraphs (b) and (c) above cannot be waived by any of the parties to the Subscription Agreement.

In the event that any of the above Conditions is not fulfilled (or, where appropriate, waived) before the Long Stop Date, the Subscription Agreement shall terminate and shall cease to have any effect on any of the parties to the Subscription Agreement, save for any antecedent breaches thereof.

Closing

Closing shall take place on the fifth business day after the fulfilment (or, where appropriate, waiver) of all the Conditions under the Subscription Agreement or such other day as may be agreed by the parties thereto in writing.

RANKING OF THE SUBSCRIPTION SHARES

The Subscription Shares will rank, upon allotment and issue, *pari passu* in all respects with each other, among themselves and with the other Shares in issue on the date of allotment and issue of the Subscription Shares at Closing. The Subscription Shares shall be allotted and issued by the Company free from all liens, charges, security interests, encumbrances or other third party rights together with all rights attaching thereto on and after the date of their allotment, including all dividends which are made or proposed to be made at any time by reference to a record date falling on or after the date of allotment of the Subscription Shares.

GENERAL MANDATE TO ALLOT AND ISSUE THE SUBSCRIPTION SHARES

No Shareholders' approval is required for the Subscription and the allotment and issue of the Subscription Shares by the Company, as the Subscription Shares will be allotted and issued pursuant to the General Mandate granted to the Board by a resolution of the Shareholders passed at the EGM held on December 4, 2025, under which the Board may allot, issue and deal with new Shares not exceeding 102,165,296 new Shares (representing approximately 20% of the issued Shares as at the date of the passing of the resolution at the EGM (excluding treasury shares)).

As at the date of the Subscription Agreement, no Share had been issued under the General Mandate. As such, 102,165,296 Shares could still be issued under the General Mandate.

APPLICATION FOR LISTING OF THE SUBSCRIPTION SHARES

An application will be made by the Company to the Stock Exchange for the listing of, and the permission to deal in, the Subscription Shares on the Stock Exchange.

The Subscription is conditional upon, among other things, the Stock Exchange granting the listing of, and permission to deal in, the Subscription Shares.

CSRC FILINGS

The Company shall complete the CSRC Filings in connection with the Subscription.

REASONS FOR AND BENEFITS OF THE SUBSCRIPTION AND USE OF PROCEEDS

The gross proceeds of the Subscription will amount to approximately HK\$200,000,000 and the net proceeds receivable by the Company under the Subscription are estimated to be approximately HK\$199,000,000 after deducting the relevant expenses incurred in relation to the Subscription. The net issue price per Subscription Share is HK\$2.37. The Company intends to use the net proceeds from the Subscription for the following purposes:

Intended use of proceeds	Percentage of net proceeds	Target time for use of proceeds
Working capital and registration maintenance of commercialized products	12%	2027
Research and development expenses for existing pipeline of products	28%	2027
Settling trade payables of the Group	60%	2026
Total	100%	

Taking into account the financial position of the Group and the portion of the proceeds from the subscriptions in August 2025 and September 2025 having been used up to the date of the Subscription Agreement, the Directors consider that the Subscription offer a good opportunity to raise further capital for, among others, its research and development activities and registration maintenance of commercialized products and to reduce the Group's trade payables. While the proceeds from the subscriptions announced on August 13, 2025 and September 15, 2025 are partly planned for use in the research and development of existing pipeline of products, the above intended use of proceeds from the Subscription is to supplement the amount raised in August 2025 and September 2025.

Having considered the above, the Directors (including the independent non-executive Directors) are of the view that the Subscription are in the interests of the Company and the Shareholders as a whole.

EFFECTS OF THE SUBSCRIPTION ON SHAREHOLDING STRUCTURE OF THE COMPANY

As at the date of this announcement, the number of the total issued Shares of the Company is 511,228,234 Shares.

The table below sets out a summary of the shareholding structure of the Company (i) as at the date of this announcement; and (ii) immediately upon the Closing (assuming there is no change in the number of issued Shares up to the Closing Date):

	As at the date of this announcement		Immediately upon the Closing (assuming there is no change in the number of issued Shares up to the Closing Date)	
	Number of issued Shares	Approximate percentage in the issued share capital of the Company (%) ⁽¹⁾	Number of issued Shares	Approximate percentage in the issued share capital of the Company (%) ⁽¹⁾
Shareholders				
Dr. James Xue	26,042,380 ⁽²⁾	5.09	26,042,380 ⁽²⁾	4.37%
	15,000,000 ⁽³⁾	2.93	15,000,000 ⁽³⁾	2.52%
	839,141 ⁽⁴⁾	0.16	839,141 ⁽⁴⁾	0.14%
Mr. James Arthur Geraghty	700,000	0.14	700,000	0.12%
Baheal	97,149,468	19.00	97,149,468	16.32%
Subscriber	12,826,080	2.51	96,859,693	16.27%
Other public Shareholders	358,671,165	70.16	358,671,165	60.25%
Total number of Shares	511,228,234	100%	595,261,847	100%

Note:

- (1) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.
- (2) CTX Pharma Holdings Limited directly held 26,042,380 Shares and is wholly-owned by Dr. Xue.

- (3) 15,000,000 Shares are held by JQX 2021 Gift Trust (a trust set up by Dr. Xue as settlor, the spouse of Dr. Xue as trustee and Dr. Xue's family members as the beneficiaries, the "**Family Trust**"). Under the terms of the Family Trust, Dr. Xue has the power to exercise all the voting rights attached to the Shares. Accordingly, Dr. Xue is deemed interested in the Shares held by the Family Trust.
- (4) Dr. Xue beneficially holds 733,050 Shares under his own name and 106,091 Shares via a nominee which were derived from the exercising of share options.

EQUITY FUND RAISING ACTIVITIES OF THE COMPANY DURING THE PAST TWELVE MONTHS

The Company has conducted the following equity fund raising activities in the past twelve months immediately preceding the date of this announcement:

Date of announcement	Fund raising activity	Net proceeds raised (approximately)	Intended use of proceeds	Actual use of proceeds
August 13, 2025	Subscription of new Shares under general mandate	HK\$98,661,767	(i) research and development of commercialized products, (ii) marketing and promotion activities, (iii) repayment of loan facilities and borrowings, and (iv) daily operations of the Group.	Approximately HK\$67,186,255.97
August 27, 2025 (on completion of the subscription)				has been used as at the date of this announcement.
September 15, 2025	Subscription of new Shares under general mandate	HK\$22,091,402.96	(i) research and development expenses for existing pipeline of products and (ii) daily operations of the Group.	Approximately HK\$17,290,452.71
September 28, 2025 (on completion of the subscription)				has been used as at the date of this announcement.
				The timeline for the use of the remaining proceeds will be in accordance with the announcement dated August 13, 2025.
				The timeline for the use of the remaining proceeds will be in accordance with the announcement dated September 15, 2025.

Closing is subject to fulfilment (or, where appropriate, waiver) of the conditions precedent under the Subscription Agreement. As the Subscription may or may not proceed, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

DEFINITIONS

In this announcement, unless the context requires otherwise, the following expressions shall have the following meanings.

“Baheal”	Baheal Wellness Industry International Trading Limited (百洋健康產業國際商貿有限公司), a company incorporated under the laws of Hong Kong with limited liability
“Board”	the board of Directors
“business day(s)”	any day (excluding a Saturday, Sunday or public holiday in the PRC or Hong Kong) on which licensed banks generally are open for business and the Stock Exchange is open for trading of securities in Hong Kong
“Closing”	the closing of the Subscription pursuant to the terms and conditions of the Subscription Agreement
“Closing Date”	the date on which Closing takes place
“Company”	CANbridge Pharmaceuticals Inc. (北海康成製藥有限公司), an exempted company incorporated in the Cayman Islands with limited liability on January 30, 2018, the Shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 1228)
“connected person(s)”	has the same meaning ascribed thereto under the Listing Rules
“CSRC”	the China Securities Regulatory Commission
“CSRC Filings”	the CSRC Filing Report (including any amendments, supplements and/or modifications thereof) and any relevant supporting materials
“CSRC Filing Report”	the filing report in relation to the Subscription and any transactions contemplated by the Subscription Agreement to be filed with the CSRC
“Director(s)”	the director(s) of the Company
“EGM”	the extraordinary general meeting of the Company held on December 4, 2025

“General Mandate”	the general mandate granted by a resolution passed at the EGM to the Board to allot, issue and deal with new Shares not exceeding approximately 20% of the total number of Share in issue as at the date of passing of the resolution (excluding treasury shares), that is a total of 102,165,296 new Shares
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	Hong Kong Special Administrative Region of the PRC
“Last Trading Day”	February 13, 2026, being the last trading day immediately prior to the signing of the Subscription Agreement
“Long Stop Date”	being one month after the date of the Subscription Agreement or such other date as may be agreed by the parties thereto in writing
“PRC”	the People’s Republic of China which, for the purpose of this announcement, shall exclude Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Share(s)”	ordinary share(s) in the share capital of the Company with a par value of US\$0.00001 each
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscriber”	WuXi Biologics HealthCare Venture
“Subscription”	the subscription for an aggregate of the Subscription Shares by the Subscriber on the terms and subject to the conditions set out in the respective Subscription Agreement
“Subscription Agreement”	the conditional subscription agreement entered into between the Company and the Subscriber dated February 15, 2026
“Subscription Price”	the price of HK\$2.38 per Subscription Share
“Subscription Share(s)”	an aggregate of 84,033,613 new Shares to be allotted and issued pursuant to the terms and conditions of the Subscription Agreement
“substantial shareholder”	has the meaning ascribed to it under the Listing Rules

“US\$” United States dollars, the lawful currency of United States

“%” per cent

By Order of the Board
CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
Dr. James Qun Xue
Chairman

Hong Kong, February 16, 2026

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Ms. Zhao Wei and Mr. Wang Tingwei as non-executive Directors, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.

* *For identification purpose only*